Insmed Insiders Sold US$3.8m Of Shares Suggesting Hesitancy

Simply Wall StNov 23 02:25

Insmed Is Maintained at Overweight by JP Morgan

Dow JonesNov 22 23:01 · Ratings

Demystifying Insmed: Insights From 7 Analyst Reviews

BenzingaNov 22 23:00

Insmed Analyst Ratings

BenzingaNov 22 22:50 · Ratings

J.P. Morgan Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $83

Futu NewsNov 22 19:32 · Ratings

Optimistic Revenue Forecast for Insmed Following Brensocatib's Launch and Strategic Developments

TipRanksNov 22 19:27